DexCom, Inc. (DXCM) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1,959.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 47,370 shares of the medical device company’s stock after purchasing an additional 45,070 shares during the period. Daiwa Securities Group Inc. owned 0.05% of DexCom worth $2,719,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in shares of DexCom by 29.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after purchasing an additional 1,991,094 shares during the last quarter. Brown Advisory Inc. raised its position in shares of DexCom by 57.2% during the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after purchasing an additional 1,515,134 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of DexCom by 143.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after purchasing an additional 7,738,678 shares during the last quarter. State Street Corp raised its position in shares of DexCom by 2.5% during the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after purchasing an additional 37,581 shares during the last quarter. Finally, AXA raised its position in shares of DexCom by 10.5% during the 3rd quarter. AXA now owns 1,318,931 shares of the medical device company’s stock worth $64,529,000 after purchasing an additional 124,920 shares during the last quarter.

In other news, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the sale, the insider now owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $55.53, for a total transaction of $90,791.55. Following the completion of the sale, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at approximately $3,612,170.97. The disclosure for this sale can be found here. In the last three months, insiders sold 48,140 shares of company stock valued at $2,743,281. Corporate insiders own 1.70% of the company’s stock.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at $54.67 on Wednesday. DexCom, Inc. has a one year low of $42.62 and a one year high of $86.32. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. The firm has a market cap of $4,752.73, a P/E ratio of -95.91 and a beta of 0.21.

A number of analysts have commented on the stock. BMO Capital Markets increased their price objective on shares of DexCom to $74.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. BidaskClub upgraded shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 12th. Northland Securities downgraded shares of DexCom from a “market perform” rating to an “under perform” rating and set a $85.00 price objective for the company. in a report on Thursday, January 4th. Jefferies Group increased their price objective on shares of DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a report on Friday, December 22nd. Finally, ValuEngine downgraded shares of DexCom from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. DexCom currently has an average rating of “Hold” and an average price target of $67.44.

TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) Shares Bought by Daiwa Securities Group Inc.” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/dexcom-inc-dxcm-shares-bought-by-daiwa-securities-group-inc.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply